comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 22:45:55 - browse：16362

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Medicare Advantage enrollment grows 7.1% to 33.4 million people

explore

hotspot

WSS

CEOs share strategies for surviving biotech slump

Beam Therapeutics to lay off 20% of its staff, re

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

WATCH: Why do our ears pop?

First Opinion Podcast: Long Covid needs a new approach

Elevance, SCAN deals highlight health insurer acquisition scrutiny

leisure time

comprehensive

explore

Moonlake's readout produced a cash windfall. Risks remain

WATCH: Why do our ears pop?

Medical records are filled with copy

2023 STAT Wunderkinds: get to know the winners

Guidelines to prevent youth baseball injuries need more muscle

Abridge raises $150m as clinical notes automation market heats up

Medical records are filled with copy

Solve the antibiotic resistance crisis with preventive drugs

Activists slam private health insurers over coverage restrictions

Studies point to risks of excluding people with obesity from drug trials

knowledge

NIH confirmation hearing shows politicization of research

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

2023 STAT Wunderkinds: get to know the winners

STAT Summit: GSK CEO on pharma giant's new direction

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

explore

leisure time

hotspot

explore